4DMT to Participate in Upcoming Investor Conferences

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) said management will present and hold one-on-one investor meetings at three healthcare conferences in March 2026.

Presentations are scheduled at TD Cowen on March 3, 2026 at 10:30 a.m. ET, Leerink on March 10, 2026 at 4:20 p.m. ET, and Barclays on March 12, 2026 at 9:00 a.m. ET. Webcasts will be archived for up to one year on the company Investors site.

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March.

TD Cowen 46th Annual Health Care Conference

Presentation Date:	Tuesday, March 3, 2026
Presentation Time:	10:30 a.m. ET
Webcast Link:	Webcast

Leerink Global Healthcare Conference

Presentation Date:	Tuesday, March 10, 2026
Presentation Time:	4:20 p.m. ET
Webcast Link:	Webcast

Barclays 28th Annual Global Healthcare Conference

Presentation Date:	Thursday, March 12, 2026
Presentation Time:	9:00 a.m. ET
Webcast Link:	Webcast

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

About 4DMT         

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

When will 4D Molecular Therapeutics (FDMT) present at the TD Cowen 46th Annual Health Care Conference?

The FDMT presentation is scheduled for Tuesday, March 3, 2026 at 10:30 a.m. ET. According to the company, management will present live and participate in one-on-one investor meetings with a webcast available and archived on the company Investors site.

What time is 4DMT speaking at the Leerink Global Healthcare Conference on March 10, 2026?

4DMT is scheduled to speak on Tuesday, March 10, 2026 at 4:20 p.m. ET. According to the company, management will present and hold meetings, and a webcast of the presentation will be available and archived on the company Investors page.

How can investors watch the 4D Molecular Therapeutics (FDMT) Barclays conference presentation on March 12, 2026?

Investors can watch via the live webcast for the March 12, 2026 9:00 a.m. ET Barclays presentation. According to the company, the webcast link will be provided and archived for up to one year on the company Investors website.

Will 4DMT archive the March 2026 conference webcasts and for how long?

Yes. According to the company, archived copies of the webcasts will be available for up to one year. Investors can access archived presentations via the Investors section at https://ir.4dmoleculartherapeutics.com/events.

Which investor conferences will 4D Molecular Therapeutics (FDMT) attend in March 2026?

The company will attend TD Cowen, Leerink Global Healthcare, and Barclays Global Healthcare conferences in March 2026. According to the company, management will present and take part in one-on-one investor meetings at each event with webcasts provided.

Does 4DMT plan one-on-one investor meetings during the March 2026 conference schedule?

Yes. According to the company, management will present and also participate in one-on-one investor meetings at the listed March 2026 conferences to engage with investors and analysts.